Literature DB >> 10768986

Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis.

M K Hondalus1, S Bardarov, R Russell, J Chan, W R Jacobs, B R Bloom.   

Abstract

Attenuated mutants of Mycobacterium tuberculosis represent potential vaccine candidates for the prevention of tuberculosis. It is known that auxotrophs of a variety of bacteria are attenuated in vivo and yet provide protection against challenge with wild-type organisms. A leucine auxotroph of M. tuberculosis was created by allelic exchange, replacing wild-type leuD (Rv2987c), encoding isopropyl malate isomerase, with a mutant copy of the gene in which 359 bp had been deleted, creating a strain requiring exogenous leucine supplementation for growth in vitro. The frequency of reversion to prototrophy was <10(-11). In contrast to wild-type M. tuberculosis, the DeltaleuD mutant was unable to replicate in macrophages in vitro. Its attenuation in vivo and safety as a vaccine were established by the fact that it caused no deaths in immunodeficient SCID mice. Complementation of the mutant with wild-type leuD abolished the requirement for leucine supplementation and restored the ability of the strain to grow both in macrophages and in SCID mice, thus confirming that the attenuated phenotype was due to the DeltaleuD mutation. As a test of the vaccine potential of the leucine auxotroph, immunocompetent BALB/c mice, susceptible to fatal infection with wild-type M. tuberculosis, were immunized with the DeltaleuD mutant and subsequently challenged with virulent M. tuberculosis by both the intravenous and aerosol routes. A comparison group of mice was immunized with conventional Mycobacterium bovis BCG vaccine. Whereas all unvaccinated mice succumbed to intravenous infection within 15 weeks, mice immunized with either BCG or the DeltaleuD mutant of M. tuberculosis exhibited enhanced and statistically equivalent survival curves. However, the leuD auxotroph was less effective than live BCG in reducing organ burdens and tissue pathology of mice challenged by either route. We conclude that attenuation and protection against M. tuberculosis challenge can be achieved with a leucine auxotroph and suggest that to induce optimal protection, attenuated strains of M. tuberculosis should persist long enough and be sufficiently metabolically active to synthesize relevant antigens for an extended period of time.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768986      PMCID: PMC97501          DOI: 10.1128/IAI.68.5.2888-2898.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  60 in total

1.  The effects of biochemical mutation on the virulence of Bacterium typhosum: the virulence of mutants.

Authors:  G A BACON; T W BURROWS; M YATES
Journal:  Br J Exp Pathol       Date:  1950-12

2.  Modeling the impact of global tuberculosis control strategies.

Authors:  C J Murray; J A Salomon
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

3.  Insertional mutagenesis and illegitimate recombination in mycobacteria.

Authors:  G V Kalpana; B R Bloom; W R Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

4.  Characterization of aromatic- and purine-dependent Salmonella typhimurium: attention, persistence, and ability to induce protective immunity in BALB/c mice.

Authors:  D O'Callaghan; D Maskell; F Y Liew; C S Easmon; G Dougan
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

5.  Construction and characterization in vivo of Bordetella pertussis aroA mutants.

Authors:  M Roberts; D Maskell; P Novotny; G Dougan
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

6.  Leucine auxotrophy restricts growth of Mycobacterium bovis BCG in macrophages.

Authors:  F C Bange; A M Brown; W R Jacobs
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

7.  BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life.

Authors:  P D Hart; I Sutherland
Journal:  Br Med J       Date:  1977-07-30

8.  Mutants of Salmonella typhimurium that cannot survive within the macrophage are avirulent.

Authors:  P I Fields; R V Swanson; C G Haidaris; F Heffron
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

9.  The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages.

Authors:  Y Yuan; D D Crane; R M Simpson; Y Q Zhu; M J Hickey; D R Sherman; C E Barry
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

10.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

View more
  101 in total

1.  The stringent response of Mycobacterium tuberculosis is required for long-term survival.

Authors:  T P Primm; S J Andersen; V Mizrahi; D Avarbock; H Rubin; C E Barry
Journal:  J Bacteriol       Date:  2000-09       Impact factor: 3.490

2.  Comprehensive identification of conditionally essential genes in mycobacteria.

Authors:  C M Sassetti; D H Boyd; E J Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

3.  Construction and phenotypic characterization of an auxotrophic mutant of Mycobacterium tuberculosis defective in L-arginine biosynthesis.

Authors:  Bhavna G Gordhan; Debbie A Smith; Heidi Alderton; Ruth A McAdam; Gregory J Bancroft; Valerie Mizrahi
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

4.  Crystal structure of LeuA from Mycobacterium tuberculosis, a key enzyme in leucine biosynthesis.

Authors:  Nayden Koon; Christopher J Squire; Edward N Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-24       Impact factor: 11.205

5.  Application of a high-throughput fluorescent acetyltransferase assay to identify inhibitors of homocitrate synthase.

Authors:  Stacie L Bulfer; Thomas J McQuade; Martha J Larsen; Raymond C Trievel
Journal:  Anal Biochem       Date:  2010-11-10       Impact factor: 3.365

6.  Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

Authors:  Vasan K Sambandamurthy; Steven C Derrick; Kripa V Jalapathy; Bing Chen; Robert G Russell; Sheldon L Morris; William R Jacobs
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

7.  Mutually dependent secretion of proteins required for mycobacterial virulence.

Authors:  S M Fortune; A Jaeger; D A Sarracino; M R Chase; C M Sassetti; D R Sherman; B R Bloom; E J Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-19       Impact factor: 11.205

8.  Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain.

Authors:  D Aguilar; E Infante; C Martin; E Gormley; B Gicquel; R Hernandez Pando
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

9.  Starvation survival response of Mycobacterium tuberculosis.

Authors:  Tanya Parish
Journal:  J Bacteriol       Date:  2003-11       Impact factor: 3.490

10.  Arginine-deprivation-induced oxidative damage sterilizes Mycobacterium tuberculosis.

Authors:  Sangeeta Tiwari; Andries J van Tonder; Catherine Vilchèze; Vitor Mendes; Sherine E Thomas; Adel Malek; Bing Chen; Mei Chen; John Kim; Tom L Blundell; Julian Parkhill; Brian Weinrick; Michael Berney; William R Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.